Results 11 to 20 of about 22,196 (255)

Repurposing of Bromocriptine for Cancer Therapy

Frontiers in Pharmacology, 2018
Bromocriptine is an ergot alkaloid and dopamine D2 receptor agonist used to treat Parkinson’s disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus.
Ean-Jeong Seo, Yoshikazu Sugimoto, Henry Johannes Greten, Thomas Efferth   +3 more
doaj   +2 more sources

Bromocriptine and insulin sensitivity in lean and obese subjects

Endocrine Connections, 2016
Bromocriptine is a glucose-lowering drug, which was shown to be effective in obese subjects with insulin resistance. It is usually administered in the morning. The exact working mechanism of bromocriptine still has to be elucidated.
L Bahler, H J Verberne, E Brakema, R Tepaske, J Booij, J B Hoekstra, F Holleman   +6 more
doaj   +2 more sources

The Effects of Bromocriptine on Preventing Postpartum Flare in Systemic Lupus Erythematosus Patients from South China

Journal of Immunology Research, 2015
Objective. Prolactin plays an important role on the disease flare of postpartum SLE patients. 76 pregnant SLE patients were enrolled in this study to evaluate the efficacy of bromocriptine (an inhibitor of prolactin secretion) on preventing the ...
Qiu Qian, Liang Liuqin, Li Hao, Yuan Shiwen, Zhan Zhongping, Chen Dongying, Lian Fan, Xu Hanshi, Yang Xiuyan, Ye Yujin   +9 more
doaj   +2 more sources

Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study

Journal of Diabetes Research, 2015
Background. The concurrent use of a postprandial insulin sensitizing agent, such as bromocriptine-QR, a quick release formulation of bromocriptine, a dopamine D2 receptor agonist, may offer a strategy to improve glycemic control and limit/reduce insulin ...
Erin D. Roe, Bindu Chamarthi, Philip Raskin   +2 more
doaj   +2 more sources

Bromocriptine inhibits proliferation in the endometrium from women with adenomyosis

Frontiers in Endocrinology, 2023
ObjectiveBromocriptine treatment has been shown to reduce menstrual bleeding and pain in women with adenomyosis in a pilot clinical trial. The underlying mechanism contributing to the treatment effect is however unknown.
Yiqun Tang, Sakthivignesh Ponandai-srinivasan, Caroline Frisendahl, Johanna K. Andersson, Dora Pavone, Elizabeth A. Stewart, Parameswaran Grace Luther Lalitkumar, Eberhard Korsching, Nageswara Rao Bogavarappu, Kristina Gemzell-Danielsson   +9 more
doaj   +1 more source

Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas

International Journal of Medical Sciences, 2020
Prolactinomas are the most common type of functional pituitary adenoma. Although bromocriptine is the preferred first line treatment for prolactinoma, resistance frequently occurs, posing a prominent clinical challenge. Both the prolactin receptor (PRLR)
Zhengzheng Xiao, Xiaoli Yang, Kun Zhang, Zebin Liu, Zheng Shao, Chaojun Song, Xiaobin Wang, Zhengwei Li   +7 more
semanticscholar   +1 more source

THE EFFECT OF BROMOCRIPTINE ON C-REACTIVE PROTEIN IN WOMEN WITH HYPERPROLACTINEMIC AMENORRHEA [PDF]

The Medical Journal of Basrah University, 2008
C-reactive protein has become the subject of avid interest in recent years. Increased concentrations of C-reactive protein (CRP) became widely accepted as a risk factor of many inflammatory diseases including atherosclerosis, ischemic vascular diseases ...
Isam Hamo Mahmood
doaj   +1 more source

Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study

BMC Endocrine Disorders, 2020
Background Whether lower dose cabergoline therapy for hyperprolactinemia increases risk of valvular dysfunction remains controversial. We examined valvular abnormalities among asymptomatic adults with hyperprolactinemia treated with dopamine agonists ...
Amer Budayr, Thida C. Tan, Joan C. Lo, Jonathan G. Zaroff, Grace H. Tabada, Jingrong Yang, Alan S. Go   +6 more
doaj   +1 more source

Rapid and dramatic glucose‐lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma

Journal of Diabetes Investigation, 2021
Dopamine receptor agonists are typically used to treat Parkinson’s disease and certain pituitary tumors, such as prolactinoma or a growth hormone‐producing tumor.
Motoyuki Igata, Yoshitaka Yagi, Satoko Hanatani, Masaji Sakaguchi, Norio Ishii, Kayo Yoshinaga, Junji Kawashima, Hiroyuki Motoshima, Eiichi Araki   +8 more
doaj   +1 more source

Bromocriptine in Parkinsonism. [PDF]

BMJ, 1978
A review of the effects of using bromocriptine in Parkinson's disease showed that it rarely helps patients not primarily improved by levodopa. Patients who show late failure with levadopa and whose response to treatment is declining are helped by combining the two drugs.
John Pearce, Iris Pearce
openaire   +3 more sources